Abstract
The fragmentation patterns of whole genome sequenced cell-free DNA are promising features for tumor-agnostic cancer detection. However, systematic biases challenge their cross-cohort generalization. We introduce LIONHEART, a novel, open source cancer detection method specifically optimized to generalize across datasets. The method correlates bias-corrected cfDNA fragment coverage across the genome with the locations of accessible chromatin regions from 487 cell and tissue types. We use these correlations to detect changes in the cell-free DNA cell type composition caused by cancer. We test LIONHEART on eight datasets and twelve cancer types (1083 non-cancer controls, 1251 cancers) obtained from different studies and show that it can distinguish cancer samples from non-cancer controls across cohorts with ROC AUC scores ranging from 0.59-0.91 (mean = 0.80, std = 0.11). We further validate the method on an external dataset, achieving a ROC AUC of 0.859.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Aarhus University Research Foundation (grant no. AUFF-F-2020-7-8 to S.B.), the Novo Nordisk Foundation (grant no. NNF22OC0074415 to C.L.A.), the Danish Cancer Society (grant numbers R146-A9466-16-S2 (C.L.A.), R231-A13845 (C.L.A.), and R257-A14700 (C.L.A.)). Delfi Diagnostics Inc. covered the cost of sequencing the Endoscopy II symptomatic colorectal cancer cohort. The Aarhus prostate cancer studies were supported by grants from the Novo Nordisk Foundation (no. NNF20OC0059410 to K.D.S) and the Danish Cancer Society (no. R281-A16122 to K.D.S. and no. R306-A18131 to M.R.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This manuscript contained three separate cohorts with the following approvals. The Scientific Ethics Committees for the Capital Region of Denmark approved the Endoscopy II study (j. no H-3-2009-110). The GDPR-compliant Danish Data Protection Agency approved the Endoscopy II study (2008-41-2252). The Danish National Committee on Health Research Ethics approved using the Endoscopy II cohort for the current analysis (j. no. 26 2001584). The Danish National Committee on Health Research Ethics approved the GECOCA study (j. no. 2208092). The prostate cancer study approved by either the Central Denmark Region Committees on Health Research Ethics (no. 1-10-72-139-15, no. 1-10-72-262-21, no. 1-10-72-367-13, and no. 1-10-14 72-337-16) or The National Committee on Health Research Ethics (no. 1302791 and no. 1901101) and notified to the Danish Data Protection Agency (no. 1-16-02-330-13, no. 1-16-02-366-15, no. 1-16-16 02-388-21, no. 1-16-02-248-14, and no. 1-16-02-686-16).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
